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Cell Biology, University of Tartu; and g Estonian Biocenter, Tartu, EstoniaObjective: To conﬁrm the effect of single nucleotide polymorphisms (SNPs) in chorionic gonadotropin beta (CGB) genes in modulating
the susceptibility to recurrent miscarriage (RM) in Danes and in a meta-analysis across Danes and the discovery samples from Estonia
and Finland.
Design: Case-control association study, restriction fragment length polymorphism genotyping, resequencing.
Setting: Fertility clinics at the Rigshospitalet, Copenhagen, and Aalborg Hospital, Aalborg, Denmark.
Patient(s): Four hundred ﬁfty Danish women and men from couples with RM and 119 women with children and no miscarriages in
new study. A total of 634 women and men from RM couples and 314 female controls in a combined study of Estonians, Finns, and
Danes.
Intervention(s): None.
Main Outcome Measure(s): Distribution of CGB5 and CGB8 allele and haplotype frequencies in patients and controls.
Result(s): For the majority of studied SNPs, the allelic and haplotypic distribution differed statistically between the Danish and the
previous Estonian-Finnish sample. In Danes, two CGB5 promoter SNPs (c5-155; c5-142) exhibited a nonsigniﬁcant trend for higher
allele frequency in fertile women compared with RM patients. The meta-analysis of results from three populations conﬁrmed
a modest but signiﬁcant effect on carriage of c5-155C (odds ratio ¼ 0.64; 95% conﬁdence interval [CI] 0.44–0.94) and c5-142A
(odds ratio ¼ 0.66; 95% CI, 0.45–0.94) variants in reducing the risk of RM. None of the investigated genetic variants in the CGB8
gene was associated with RM.
Conclusion(s): Carriage of particular variants in the promoter of the CGB5 gene seems to protect against RM. No common genetic var-Use your smartphoneiants in CGB5 and CGB8 were associated with increased RM susceptibility in the studied North
European populations. (Fertil Steril 2013;99:1930–6. 2013 by American Society for Repro-
ductive Medicine.)
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Fertility and Sterility®I n human pregnancy, the production of hCG, a placentalhormone, is indispensable. Its classical function isconsidered to maintain the production of steroid hor-
mones in the corpus luteum. In addition, hCG enhances blas-
tocyst implantation, uterine vascularization, and
angiogenesis, as well as regulates maintenance of uterine
quiescence and immunological adaptation during pregnancy
(1–3). Low levels of hCG during the ﬁrst trimester of
pregnancy are related to miscarriage and extrauterine
pregnancy (4–6). Abnormal circulating levels of hCG and
alterations in the hormone's glycosylation patterns have
been described in several pathologies (trisomies, gestational
trophoblastic diseases, malignant tumors, etc.) and implied
in clinical diagnostics (3, 7, 8).
A clinical condition that may develop from low hCG is re-
current miscarriage (RM), deﬁned as three or more consecu-
tive pregnancy losses before 22 gestational weeks (9). Apart
from the known risk factors for RM (parental chromosomal
anomalies, maternal thrombophilic, anatomical, endocrine,
or immunological disorders), >50% of the RM cases remain
classiﬁed as idiopathic (10). As the prevalence of miscarriage
among the ﬁrst-degree relatives of the women with RM is in-
creased (11), a notable fraction of unexplained RM cases is ex-
pected to represent carriers of genetic risk factors involved in
RMpathogenesis. Due to an irreplacable role of hCG in normal
gestation, genetic variants in genes encoding hCG subunits
may affect gene expression and consequently the optimal
levels of hormone production as well as pregnancy success.
HCG is a heterodimeric glycoprotein consisting of two
dissimilar subunits, a and b. The a-subunit gene is shared
among gonadotropins (hCG, LH, FSH) and TSH, whereas the
b-subunit is hormone speciﬁc. In humans, the b-subunit of
hCG is coded by four duplicated and highly homologous
(97%–99% DNA identity) chorionic gonadotropin beta (CGB)
genes (12–15). All CGB genes encode identical hCG b-
subunit proteins, which are critical to the level of intact
circulating hCG (16). Still, the transcriptional activity
among gene duplicates varies greatly, and there is also
a large interindividual variation in the hCGbeta transcript
levels (6, 17, 18). The majority, up to 82%, of the total pool
of hCGbeta transcripts is provided by two genes, CGB8 and
CGB5 (6, 18).
We have recently conducted a clinical resequencing study
of CGB5 and CGB8 genes among Estonian and Finnish pa-
tients with RM and fertile controls (19). The study identiﬁed
three rare variations in the protein-coding exons resulting
in amino acid changes in the hCG-beta protein (Val56Leu in
CGB5; Arg8Trp and Pro73Arg in CGB8), and they may there-
fore be potential risk factors for the occurrence of RM. The
subsequent detailed functional and structural analysis of
these mutations concluded that only substitutions with neu-
tral or mild functional consequences for hCG action might
be tolerated in the major hCG-beta coding genes CGB5 and
CGB8 (20). Additionally, the resequencing described six sin-
gle nucleotide polymorphisms (SNPs) in the CGB5 and
CGB8 genes located outside the exons with signiﬁcantly
lower frequency among RM patients compared with the con-
trol group and thus exhibiting a protective effect towards RM
(19). These polymorphisms included four linked SNPs (c5-VOL. 99 NO. 7 / JUNE 2013155G/C/c5-147G/del/c5-144T/C/c5-142T/A) in the
upstream of the CGB5 gene (up to 350 bp relative to mRNA
start site), which form the two main CGB5 promoter haplo-
types that are composed of the combination of either major
or minor alleles of these SNPs (Fig. 1). Association with RM
susceptibility was also detected for two intronic SNPs in the
CGB5 (c5þ1038C/T) and CGB8 genes (c8þ1045C/T)
(Fig. 1).
This study aimed [1] to conﬁrm the effect of the CGB5
(c5-155G/C, c5-142T/A, c5þ1038C/T) and CGB8
(c8þ1045C/T) polymorphisms on the susceptibility to RM
by genotyping an independent sample set from Denmark
and by an extended meta-analysis across the three study
populations (Estonians, Finns, Danes); [2] to resequence the
promoter region of the most actively transcribed hCG-beta-
coding gene CGB8 in the Danish RM cases and controls to
discover novel potential genetic risk variants to RM. The
meta-analysis conﬁrmed a modest but signiﬁcant effect of
the CGB5 promoter variants c5-155C and c5-142A in reduc-
ing the risk to RM. Other investigated SNPs in the CGB5 and
CGB8 genes exhibited no effect on RM susceptibility.SUBJECTS AND METHODS
Study Subjects
Subjects recruited in the study were admitted to the Fertility
Clinic, Rigshospitalet, Copenhagen, and the Department of
Obstetrics and Gynaecology, Aalborg Hospital, Aalborg,
from all over Denmark for investigation and treatment. The
study sample set included 450 Caucasian patients diagnosed
with RM (three or more pregnancy losses conﬁrmed by the
hospital records). The group of Danish idiopathic RM cases
consisted of 199 couples and 52 single female patients. Be-
cause maternally and paternally derived gene variants con-
tribute equally to the function of the fetal genome in
placenta, the patient group included both the women and
their partners who had experienced RM. In the Estonian-
Finnish discovery study (19) as well as in the current Danish
follow-up study, the control group was designed under the as-
sumption that fertile women with no history of miscarriage
are carrying gene variants supporting successful pregnancies.
The male partners were not investigated among the control
group because detailed reliable information on their repro-
ductive history is challenging to collect. The Danish control
group comprised 119 Caucasian age-matched fertile women
from couples with no history of miscarriage and at least
two normal pregnancies. None of the recruited female pa-
tients had uterine abnormalities found by hysteroscopy, uter-
ine hydrosonography, or hysterosalpingography, and all RM
patients and their husbands had normal karyotypes. All
women were regularly menstruating with a cycle length of
<35 days, and all had normal plasma thyroxin levels (detailed
in [21, 22]). The study was approved by the Ethics Committees
of the Capital Region, Denmark.
The subsequent meta-analysis combined the Danish data
set from the current study with the discovery data of the
Estonian-Finnish sample (19). The patient group of unex-
plained RM comprised 35 couples and 29 single female1931
FIGURE 1
Genomic content of the studied polymorphisms in the CGB5 and CGB8 genes. (A) Design of the RFLP experiment for the genotyping of the Danish
RM patients and fertile controls. The exons are depicted with gray boxes. A bold arrow shows the direction of gene transcription. The positions of
the PCR primers (1F to 4F, 1R to 4R; Supplemental Table 1) for the ampliﬁcation of the CGB5 and CGB8 genic regions are depicted with short
arrows. The ﬂanking regions of the genotyped SNPs (c5-155, c5-142, c5þ1038, c8þ1045) have been zoomed in and aligned between the two
duplicate genes. Dots indicate identical nucleotides in the corresponding positions of CGB5 and CGB8. The SNP code corresponds to the gene
name (c5 ¼ CGB5) and location relative to mRNA start site. The LD between the four polymorphisms in the CGB5 promoter region is expressed
using the r2-statistic. (B) The SNPs identiﬁed in Danes within the resequenced region of CGB8 spanning the upstream region (350 bp from
mRNA start site) and the ﬁrst exon (gray box; up to þ400 bp). The proximal promoter of the hCGbeta coding CGB genes necessary for full
basal expression has been demonstrated to be located between nucleotide positions 362 and þ104 relative to mRNA start site (31). The
direction of gene transcription is shown with a bold arrow. Singleton SNPs are marked with ‘‘S,’’ rare SNPs (MAF, <10%) with short
bidirectional vertical lines and common SNPs (MAF R10%) with the long vertical lines. The position c8-186 is in strong LD with the SNP
c8þ108 in CGB8 exon 1; r2 ¼ 0.896, 0.971, and 1.0 in Danes, Estonians, and Finns, respectively. All SNPs are listed in Table 1.
Rull. CGB5 promoter haplotype and recurrent miscarriage. Fertil Steril 2013.
ORIGINAL ARTICLE: EARLY PREGNANCYpatients from Estonia and 40 couples and ﬁve single female
patients from Finland. For the RM patients, the recruitment
criteria in the three study centers were identical. The
Estonian-Finnish control group was formed from age-
matched fertile women with no history of miscarriage and
consisted of 95 Estonians and 100 Finns (19). The deﬁnition
of fertile female controls in the discovery study was based
on at least one (Finnish) or three (Estonian) successful deliv-
eries (the detailed description is in reference 19).Genotyping and Resequencing
DNA was extracted from peripheral blood using an in-house
protocol or Puregene DNA Isolation Kit (Gentra Systems),
which are both based on the salting-out method for DNA ex-
traction. The CGB5 (1.7 kb fragment) and CGB8 (long-range
polymerase chain reaction [PCR]8.3 kb; nested PCR2.5 kb
fragment) genomic regions were ampliﬁed using previously
described primers and PCR conditions (15, 19) (Fig. 1A,
Supplemental Table 1).
As the four SNPs (c5-155G/C; c5-147G/del; c5-
144T/C; c5-142T/A) forming the alternative CGB5 pro-
moter variants are in strong linkage disequilibrium (LD) (r2
¼ 0.9–1.0; Fig. 1A), only two of them (c5-155, rs72553899;1932c5-142, rs72553901) were selected for genotyping as the
marker SNPs for the major CGB5 promoter haplotypes. For
these two polymorphisms capturing the core CGB5 promoter
variation and for the two intronic SNPs located at the identi-
cal position within CGB5 (c5þ1038, rs4802541) and CGB8
(c8þ1045, rs4802541), the genotypes were assessed by re-
striction fragment length polymorphism (RFLP) analysis. De-
tailed information and restriction analysis scheme are shown
in Supplemental Figure 1 and Supplemental Table 2.
The 50-upstream gene regulatory region of CGB8 was
subjected to full resequencing, covering from 350 bp up-
stream relative to the mRNA start site to the end of exon 1
(at þ400 bp). Primer design for the additional PCR ampliﬁca-
tion and sequencing primers was implemented using the
Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi). Sequences were resolved using ABI
3730 XL DNA Analyzer (Applied Biosystems) and analyzed
by the Phred, Phrap and Consed package (23), which facili-
tates base calling from sequencing trace ﬁles, sequence qual-
ity assessment, and assembly. Polymorphisms were identiﬁed
using the PolyPhred program (ver. 6.02.) (24) and conﬁrmed
by manual checking. A genetic variant was called only if it
was observed in both forward and reverse orientations. The
nomenclature of the polymorphisms was based on theVOL. 99 NO. 7 / JUNE 2013
Fertility and Sterility®following GenBank reference sequences: NM_033043.1
GI:15451747 for CGB5; NM_033183.2, GI:146229337 for
CGB8.Data Analysis
Allele frequencies were estimated, and conformance to
Hardy-Weinberg equilibrium (HWE) in the full sample as
well as in patient and control subgroups was calculated by
Fisher's exact test implemented in the GenePOP software
package (http://genepop.curtin.edu.au/index.html) (25). The
statistical tests for population differentiation comparing al-
lele and genotype frequencies of all studied SNPs among
the three populations (Danish, Estonian, Finnish) were per-
formed using GenePOP (25).
Association with the diagnosis of RM as a binary trait was
assessed by the Cochran-Armitage test for trend. Association
tests and calculation of LD between SNP pairs (r2) were per-
formed with the PLINK software, version 1.04 (http://
pngu.mgh.harvard.edu/purcell/plink/). The LD r2-statistic
represents the square of the correlation coefﬁcient between
the alleles at addressed loci.
For a meta-analysis including data from three recruit-
ment centers, the inverse-variance method was implemented
under a ﬁxed-effects model using R, version 2.7.2 (R Develop-
ment Core Team, http://www.r-project.org/). Odds ratios (OR)
with 95% conﬁdence intervals (CI) were calculated to show
the strength and direction of the association. P< .05 was con-
sidered statistically signiﬁcant.
Haplotypes within the resequenced region of CGB8 (350
bp toþ400 bp relative to mRNA start) were determined basedTABLE 1
Polymorphisms identiﬁed in CGB5 and CGB8 in the Danish sample set in
SNP, relative to mRNA start sitea Allele major/minorb Danish (n[ 5
Genotyping data
CGB5
c5-155 G/C 5.94
c5-142 T/A 5.94
c5þ1038 C/T 7.45
CGB8
c8þ1045 C/T 0.52
Resequencing data (from 350 bp to þ400)
CGB8
c8-287 T/C 29.97
c8-226 A/del 1.16
c8-196 G/A S(Co)
c8-186 G/T 26.61
c8-4 T/A 0
c8þ105 G/C 3.23
c8þ108 C/T 26.10
c8þ135 G/A S(Co)
c8þ276 G/C S(Co)
c8þ301 T/A 3.23
Note: N/A ¼ not applicable.
a An SNP code includes gene name and position of the polymorphism relative to mRNA transcriptio
b Alleles at the coding strand.
c Data from discovery study (19).
d The full genotyped sample comprising females andmales from couples with RM and fertile female c
full samples as well as in the subsamples of RMpatients and controls. S: singleton SNP carried by one
controls with no miscarriages.
Rull. CGB5 promoter haplotype and recurrent miscarriage. Fertil Steril 2013.
VOL. 99 NO. 7 / JUNE 2013on all but singleton SNPs. Singleton polymorphisms carried
in heterozygous status by one single individual were excluded
from haplotype calculations as their location on either of the
chromosomes cannot be reliably phased. Haplotypes were in-
ferred from unphased genotype data using the Bayesian sta-
tistical method in the program PHASE 2.1.1 (http://
www.stat.washington.edu/stephens/), applying the model al-
lowing recombination (26). The running parameters were
number of iterations ¼ 1,000, thinning interval ¼ 1, and
burn-in ¼ 100; the 10 parameter was used for increasing
the number of iterations of the ﬁnal run of the algorithm. The
relationship between inferred haplotypes was analyzed with
NETWORK 4.6.1.0. software (http://www.ﬂuxus-technolo-
gy.com) using the Median-Joining network algorithm (27).
Haplotype networks for CGB8 were calculated using SNPs
covering the promoter region up to the end of the ﬁrst exon.RESULTS
Frequencies of CGB5 and CGB8 SNPs and
Haplotypes Vary among North Europeans
The CGB5 SNPs subjected to genotyping by RFLP (promoter:
c5-155, c5-142; intron II: c5þ1038; Fig. 1A) exhibited signif-
icantly (Fisher's exact test, P%.002) lower allele frequency in
Danes (n¼ 569; minor allele frequency [MAF], 5.94%, 5.94%,
and 7.45%, respectively), compared with the published
Estonian-Finnish sample (9.92%, 10.58%, and 11.38%, re-
spectively; Table 1) (19). Within the resequenced region of
CGB8, the allele frequencies of common SNPs (MAF >1%,
c8-287, c8-186, c8þ108; Fig. 1B) also differed signiﬁcantly
among the study samples (P< .05; Table 1). The genotypedcomparison with individuals from Estonia and Finland.
MAF (%) in sample set
P for population comparison69)d Estonian/Finnishc (n[ 379)d
9.92 .001
10.58 < .001
11.38 .004
1.09 .137
25.21 .021
0 N/A
0 N/A
39.67 < .001
0.41(Pa) N/A
2.45 .430
39.54 < .001
0 N/A
0 N/A
5.84 .021
n start according to GenBank reference: NM_033183.2 GI:146229337 for CGB8.
ontrols; allelic distribution of all investigated CGB5 andCGB8 polymorphismswas in HWE in the
heterozygous individual; Pa: detected only among RM patients; Co: detected only among fertile
1933
FIGURE 2
ORIGINAL ARTICLE: EARLY PREGNANCYSNP in CGB8 intron II (c8þ1045) was rare among Estonians-
Finns (MAF 1.09%) and Danes (MAF 0.52%).
AmongNorthEuropeans, the resequencedCGB8gene reg-
ulatory region is represented by three core haplotypes—H2,H8,
and H11—determined by the allelic combinations of the two
unlinked (LD r2 ¼ 0.16–0.23) common polymorphisms,
c8-287 and c8-186 (Fig. 1B, Fig. 2A). In total, approximately
91% of individuals in the Danish and Estonian-Finnish study
samples carried the H2, H8, or H11 core haplotypes, although
their distribution was statistically different among popula-
tions (P%.002; Supplemental Table 3). Notably, the position
c8-186 is in strong LD (r2>0.8) with the SNP c8þ108 located
in 50UTR of CGB8 exon 1 (Fig. 1B). It is also noteworthy that
haplotype c8-287C/c8-186T combining the minor alleles of
these SNPs was missing among the genotyped individuals
(n ¼ 948), although the expected carrier frequency estimated
from the observed allele frequencies is 9%.Networks of predicted haplotypes of the resequenced region ofCGB8
spanning the upstream region (350bp frommRNAstart site) and the
ﬁrst exon (up toþ400 bp). The size of each node is proportional to the
haplotype frequency in the total analyzed data set and the length of
connecting lines is proportional to the number of mutational steps
between haplotypes. The nomenclature and detailed composition of
haplotypes are shown in Supplemental Table 3. (A) Comparison of
the haplotype distribution between the Danes (DEN; black; n ¼ 569)
and Estonians-Finns (EST/FIN; white; n ¼ 379; [19]). The haplotypes
were inferred from seven polymorphisms present more than
once among the genotyped Danish-Estonian-Finnish individuals.
(B) Comparison of the haplotype distribution between the recurrent
miscarriage (RM) cases and fertile controls within the Danish (DEN)
and the Estonian-Finnish (EST/FIN) study samples. The haplotypes in
the Danes were formed from six and in the Estonian-Finnish sample
from ﬁve polymorphisms, as some SNPs were population-speciﬁc or
occurred as singletons in either of the analyzed study population.
Rull. CGB5 promoter haplotype and recurrent miscarriage. Fertil Steril 2013.Susceptibility to RM Is Modulated by CGB5
Promoter Polymorphisms
In the Danish sample set, both genotyped SNPs in the CGB5
promoter region (c5-155; c5-142) exhibited a higher minor
allele frequency in Danish fertile women (n ¼ 119; MAF
7.14%) compared with RM patients (n ¼ 450; 5.62%). How-
ever, the difference was not statistically signiﬁcant (P¼ .367).
To increase statistical power, the genetic data of the Dan-
ish, Estonian, and Finnish recruitment centers were combined
in a meta-analysis across the three study samples (total num-
ber of 948 individuals; 634 RM patients and 314 fertile female
controls; Table 2). The carrier status of the minor alleles of the
CGB5 promoter SNPs exhibited a modest but signiﬁcant pro-
tective effect against RM occurrence (P¼ .021; c5-155: OR ¼
0.64; 95% CI, 0.44–0.94; and c5-142: OR ¼ 0.66; 95% CI,
0.45–0.94; Table 2). This result enhanced and conﬁrmed the
outcome of the original report (19). The meta-analysis includ-
ing only Danish, Estonian, and Finnish female RM patients (n
¼ 349) compared with fertile female controls (n ¼ 314)
showed the same direction and magnitude of the effect as
the analysis in the full sample, but it did not reach statistical
signiﬁcance owing to the smaller sample size (c5-155:
P¼ .116; OR ¼ 0.71; 95% CI, 0.46–1.08; c5-142: P¼ .089;
OR¼ 0.68; 95% CI, 0.44–1.06). Overall, both male and female
partners of RM couples had a lower prevalence of the minor
alleles of the studied CGB5 promoter SNPs (c5-155 and c5-
142) compared with fertile controls (Supplemental Table 4).
The allele frequencies of the genotyped intronic polymor-
phisms (CGB5: c5þ1038; CGB8: c8þ1045) did not differ be-
tween the Danish RM cases and fertile controls (MAF, 7.14%
vs. 7.42%, P¼ .52; 0.55% vs. 0.43%, P¼ .83, respectively;
Table 2).
Genetic Variation in CGB8 Promoter Does Not
Affect RM Risk
The allelic distribution of SNPs (excluding singletons) in the
resequenced CGB8 gene regulatory region (from 350 bp to
þ400 bp from mRNA start) did not differ between the Danish
RM patients and fertile controls (Supplemental Table 5), con-
ﬁrming the discovery analysis in the Estonian-Finnish sample1934(19). Concordantly, no statistical difference was detected in
the CGB8 haplotype distribution between RM patients and
fertile controls either (Fig. 2B; Supplemental Table 3). We
conclude that common genetic variants in the proximal reg-
ulatory region of CGB8 have no substantial effect on the sus-
ceptibility to RM.DISCUSSION
Previously, we showed a signiﬁcant association between six
SNPs located in the promoter region or introns of the CGB5
and CGB8 genes and reduced susceptibility to unexplained
RM among Estonians and Finns (19). The present study set
out to conﬁrm this ﬁnding in another European population
(Danes) and in a meta-analysis across the three studyVOL. 99 NO. 7 / JUNE 2013
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Fertility and Sterility®populations. The two discovery samples, representing neigh-
boring populations of Estonians and Finns, had exhibited
similar allelic distributions of SNPs in the CGB5 and CGB8
genes, whereas the allele frequencies of the Danes appeared
to be statistically different from the Estonian-Finnish sample.
A recent large-scale study showed that the geography of Eu-
ropean populations is also reﬂected in its genetic structure,
where Scandinavians cluster together with western Euro-
peans and the Estonian population is genetically closest to
Finns (28). Thus, meta-analysis rather than pooling the sam-
ples across studies is a preferred approach for increasing study
power.
As a major outcome, this study conﬁrmed the effect of the
CGB5 promoter variants on modulating the susceptibility to
RM. The carrier status of the minor alleles of the two SNPs
(c5-155, c5-142) investigated in the present study as the ge-
netic markers for the CGB5 promoter haplotypes signiﬁcantly
reduced the risk of RM (meta-analysis, P¼ .021, OR ¼ 0.64
[0.44–0.94]). This RM-protective CGB5 promoter haplotype
consists of the minor alleles of four SNPs (c5-155G/C; c5-
147G/del; c5-144T/C; c5-142T/A) and is completely
identical to the homologous region in the CGB8 gene, exhib-
iting no genetic variation in these positions (Fig. 1).
All humans have the CGB8 promoter haplotype c8-
155C/-c8147del/c8-144C/c8-142A, which seems to provide
the most optimally functioning promoter because CGB8 is re-
sponsible for up to 40% of hCG production in pregnancy (6).
Most probably, originally humans had the CGB5 gene with
a slightly less efﬁcient main promoter variant c5-155G/c5-
147G/c5-144T/c6-142T (Fig. 1A). The detected CGB5 RM-
protective haplotype c5-155C/c5-147del/c5-144C/c5-142A
originates from the CGB8 gene via a meiotic gene conversion
event between the two promoter regions (15). We speculate
that in some pregnancies, where the trophoblast growth is im-
paired (due to genetic, trombophilic, immunological, or other
reasons), the placenta with the most efﬁcient CGB5 promoter
haplotype (originating from and identical to CGB8) may have
a better capacity for extra hCG production that may eventu-
ally rescue the threatened fetuses. Subsequently, this CGB5
promoter haplotype is expected to become increasingly prev-
alent among humans and to exhibit a higher prevalence in
couples with normal fertility than in those with RM. This is
in agreement with the results of this study. We also suggest
that the current CGB8 gene with the c8-155C/c8-147del/c8-
144C/c8-142A promoter haplotype has already reached max-
imum efﬁciency. Therefore the detected common variations
in this gene have neither evolutionary advantage nor effect
on pregnancy success, and balancing selection is expected
to rapidly eliminate new, less ﬁt variants (19).
In conclusion, despite the essential role of hCG in human
pregnancy, no common SNP or haplotype variants in the
main hCGbeta coding genes (CGB5, CGB8) were associated
with increased risk of RM among the analyzed North Euro-
pean samples. Instead, the evolution in human lineage seems
to have favored the spread of CGB genetic variants (e.g., by
gene conversion), which support amore efﬁcient gene expres-
sion and may reduce the risk of pregnancy loss even in critical
situations. Recent studies have suggested that apart from
SNPs, the expression of CGB genes might be modiﬁed by1935
ORIGINAL ARTICLE: EARLY PREGNANCYepigenetic mechanisms (29, 30). A pilot study reported
polymorphic DNA methylation in the CGB5 promoter
region exclusively in placentas from RM cases leading to
expressional silencing of the paternal alleles (29). Future
larger studies have to target epigenetic modiﬁcations and
also other non-SNP variations (e.g., copy number variations,
gene deletions/duplications) in the CGB genes, which may
have clinical importance in modulating susceptibility to preg-
nancy loss.
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SUPPLEMENTAL FIGURE 1
RFLP analysis to detect polymorphisms in CGB5 and CGB8. (A, B) The PCR product of CGB5 promoter (2243 bp) is digested with (A) FastDigestStyI
(Thermo Fisher Scientiﬁc Inc./Fermentas). The substitution C/G at position155 from the transcription start ofCGB5 gives an additional fragment of
1,449 bp; lane 1, marker 100 bp DNA Ladder (Solis Biodyne); lane 2, minor homozygote; lane 3, heterozygous individual; lane 4, major
homozygote. (B) FastDigestBanI (Thermo Fisher Scientiﬁc Inc./Fermentas). The polymorphism T/A at position 142 from the transcription start
of CGB5 has an index fragment of 806 bp; lane 1, marker Gene Ruler, 100 bp DNA Ladder (Thermo Fisher Scientiﬁc Inc./Fermentas); lane 2,
heterozygous individual, lanes 3 and 4, major and minor homozygotes, respectively. (C, D) The polymorphisms located in the same position in
CGB5 and CGB8 (1038 bp and 1045 bp from transcription start) were addressed by digestion of PCR product of CGB5 (1757 bp) and CGB8
(2544 bp) with FastDigestNciI (Thermo Fisher Scientiﬁc Inc./Fermentas). In both graphs, lane 1 represents marker 100 bp DNA Ladder (Solis
Biodyne); the index fragments of 498 bp and 308 bp allow the discrimination of the major homozygote CC (C, lane 2; and D, lane 3),
heterozygous variant CT (C, lane 4; and D, lane 2), and minor homozygote TT (C, lane 3). Nomenclature is based on GenBank references:
NM_033043.1 GI:15451747 for CGB5; NM_033183.2 GI:146229337 for CGB8; and alleles represent the nucleotides on the coding strand.
The detailed restriction schema is given in Supplemental Table 2.
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SUPPLEMENTAL TABLE 1
Primers for PCR ampliﬁcation and resequencing in CGB5 and CGB8 genes and 50 upstream regions.
Primer Sequence Product size Fig.1 label
Original name
of the primera
Primers for PCR
CGB5 promoter
CGB5pr_F 50-TTTAGTAGAGACAGGGATTCACCA-30 2243 bp 1F
CGB5pr_R 50-AGACCACGGTGAAGTGATCTCAG-30 1R
CGB5 gene
CGB5_F 50-CAGGAAAGCCTCAAGTAGAGGAG-30 1757 bp 2F CGB5_3F
CGB5_R 50-CGCTCGACGATGTTTTCTATTTT-30 2R CGB5_2R
CGB8 long-range PCR
CGB8_F 50-CACGCCTGTAATTGTCGGAGGCTGT-30 8384 bp 3F CGB5/7_8kb_F3
CGB8_R 50-GAAAAGAGAGTGAAGATGGGGGACGAC-30 3R CGB5/7_8kb_R3
CGB8 nested PCR
CGB8n-F 50-CCCGGATAACTTTTCGTATTTTTA-30 2544 bp 4F CGB2_2R
CGB8n_R 50-TCCTCAGATCAACTCTCATGGAT-30 4R CGB5/7_3nestR
Primers for resequencing
CGB8 promoter and 50UTR
cgb8prom_seqF 50-CCCTGCAGTCTTACCTGGAA-30
cgb8prom_seqR 50-TGCTGTGCCAACCTATACCC-30
cgb8_1F 50-GGCCTTTGAGGAAGAGGAGT-30
cgb8_1R 50-GCCTCAGGTGGTGTGCAA-30
a Reference 15.
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SUPPLEMENTAL TABLE 2
List of addressed single nucleotides with applied restriction enzymes and fragment length.
SNPa rs No.b
Allelec major/minor
variant Restriction enzyme
Fragments present in all
variants; lenght in base pairs
Speciﬁc fragments according to
addressed nucleotide; length in base pairs
Major homozygous Minor homozygous Heterozygous
CGB5 promoter (PCR product 2245 bp)
c5-155 rs72553898
ss10510699321
G/C FastDigestStyI (Eco130I) 486 1,759 310, 1,449 310, 1,449, 1,759
c5-142 rs72553901
ss105106996
T/A FastDigestBanI (BshNI) 63, 156, 425, 492 1,109 303, 806 303, 806, 1,109
CGB5 gene (PCR product 1757 bp)
c5þ1038 rs4802541
ss105107021
C/T FastDigestNciI (BcnI) 7, 28, 79, 204, 305, 636 120, 378 498 498, 120, 378
CGB8 gene (nested PCR product 2544 bp)
c8þ1045 rs4802541
ss105107049
C/T FastDigestNciI (BcnI) 2, 7, 12, 28, 79, 204, 306, 583, 825 120, 378 498 120, 378, 498
a SNP code includes gene name (e.g., c5 ¼ CGB5) and location relative to mRNA start site; GenBank references: NM_033043.1 GI:15451747 for CGB5, NM_033183.2 GI:146229337 for CGB8.
b rs number according to NCBI SNP database.
c Alleles on the coding strand. All restriction enzymes were provided by Thermo Fisher Scientiﬁc Inc./Fermentas.
Rull. CGB5 promoter haplotype and recurrent miscarriage. Fertil Steril 2013.
V
O
L.99
N
O
.7
/JU
N
E
2013
1
9
3
6
.e3
Fertility
and
Sterility®
SUPPLEMENTAL TABLE 3
The distribution of haplotypes covering the promoter and 50 untranslated region of CGB8 among the patients with RM and fertile controls in
Danish (n[ 569) and Estonian-Finnish sample sets (n[ 379).
Haplotype
Position relative to transcription start site Estonians/Finns Danes
P valueaL287 L226 L186 L4 D105 D108 D301 RM cases
Fertile
controls All RM cases
Fertile
controls All
1 c A G T G C A 4.25 7.33 5.85 3.14 2.52 2.95 .00569
2* c A G T G C T 16.71 16.75 16.74 23.62 23.53 23.59 .00091
3 c A G T G t T 0 0 0 0.37 0.42 0.38 .09237
4 c A G T c C T 2.27 2.36 2.31 3.14 3.36 3.20 .29044
5 c A G a G C T 0.85 0 0.41 0 0 0 .07409
6 c del G T G C T 0 0 0 0.18 0.42 0.26 .16953
7 T A G T G C A 0 0 0 0 0.42 0.13 .33153
8* T A G T G C T 36.83 33.51 35.10 42.62 42.02 42.44 .00343
9 T A G T G t T 0 0 0 0.37 0.42 0.38 .09237
10 T A T T G C T 0 0 0 0.92 2.1 1.28 .00207
11* T A t T G t T 39.09 40.05 39.59 24.72 23.53 24.36 < .00001
12 T del G T G C T 0 0 0 0.18 0 0.13 .33153
13 T del t T G t T 0 0 0 0.74 1.26 0.90 .01005
Note: The major variant of a polymorphism is marked with a capital, and the minor variant with a lowercase letter. The haplotypes are in concordance with haplotype networks (Fig. 2).
a The difference between the Danish and Estonian-Finnish (Est/Fin) sample sets is calculated by the c2-test.
* Three core haplotypes.
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SUPPLEMENTAL TABLE 4
Frequencies of the minor alleles of genotyped SNPs in the CGB5 and CGB8 genes in the subgroups of male and female partners of the couples with RM compared with fertile female controls in the
Danish (n[ 569) and Estonian (n[ 194) and Finnish sample sets (n[ 185).
Polymorphism
Estonians MAF (%) Finns MAF (%) Danes MAF (%)
Fertile controls,
n[ 95
RM patients, n[ 99
Fertile controls,
n[ 100
RM patients, n[ 85
Fertile controls,
n[ 119
RM patients, n[ 450
Females,
n[ 64
Males,
n[ 35
Females,
n[ 45
Males,
n[ 40
Females,
n[ 240
Males,
n[ 210
c5-155 13.16 8.59 7.14 11.50 5.56 7.69 7.14 6.60 4.52
c5-142 11.50 8.59 7.14 13.00 5.56 7.69 7.14 6.60 4.52
c5þ1038 14.47 8.59 10.00 14.00 5.43 10.00 7.56 8.97 5.71
c8þ1045 0.53 0.78 0 3.13 0 0 0.43 0.72 0
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SUPPLEMENTAL TABLE 5
Common variants in CGB8 promoter and 50 untranslated region in
Danes (n[ 569).
SNP
MAF (%)
P value
Fertile female
controls, n[ 119
RM patients,
n[ 450
c8-287 30.74 29.52 .85
c8-226 1.79 0.94 .34
c8-186 26.84 26.38 .83
c8þ105 3.46 2.77 .83
c8þ108 25.97 26.19 .94
c8þ301 2.88 3.14 .83
Note: Association P values were calculated by the Cochran-Armitage test for trend.
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